Sun Pharma's Margin Continues To Be Driven By India, Global Specialty Sales, Says CFO
The company aims to grow faster than the Indian pharmaceutical market, says CS Muralidharan.02-02-2024
02-02-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per attached Letter.01-02-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Q3FY24 Investor Call Audio Recording Link
Q3FY24 Investor Call Audio Recording Link31-01-2024
Sun Pharmaceutical Industries Results Earnings Call for Q3FY24
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.31-01-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Gross sales at Rs 121,569 million, growth of 9.5% India formulation sales at Rs 37,785 million, up 11.4% US formulation sales at US$ 477 million, up 13.2% Global specialty sales at US$ 296 million, including US$20 million milestone received in Q3. Ex-milestones, up 24.2% Global specialty sales, ex-milestone, accounted for 19.2% of Q3FY24 sales Emerging Markets formulation sales at US$ 252 million, lower by 2.3% Rest of World formulation sales at US$ 214 million, up 12.9% R&D; investments at Rs 8,245 million compared to Rs 6,702 million for Q3FY23 EBITDA at Rs 34,768 million (including other operating revenues), up 15.8%. EBITDA margin for Q3 at 28.1% vs 26.7% during Q3FY23 Adjusted net profit (excluding the exceptional items) for Q3FY24 was Rs 25,936 million, up 19.7%. Reported net profit for Q3FY24 was Rs 25,238 million compared to Rs 21,660 mn during Q3FY23 Consolidated 9MFY24: Gross sales at Rs 359,451 million, growth of 10.4% India formulation sales at Rs 111,814 million, up 9.2% US formulation sales at US$ 1,378 million up 9.8% Emerging Markets formulation sales at US$ 796 million, up 4.5% Rest of World formulation sales at US$ 615 million, up 9.7% EBITDA at Rs 99,880 million (including other operating revenues), up 12.9%, with a resulting EBITDA margin of 27.4% Net profit for 9MFY24 was Rs 69,218 million. Like for like, adjusted net profit at Rs 73,145 million, up 12.7% The Board has declared an interim dividend of Rs 8.50 per share for the year FY24 against Rs 7.50 per share interim dividend for the previous year. Result PDF31-01-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
SPIL Q3FY24 Financial Press Release31-01-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
An interim dividend of Rs. 8.5/- per equity shares of Rs. 1/- each of the company for the FY 2023-24 is declared.31-01-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023
Unaudited Financial Results for the quarter and nine months ended December 31, 202331-01-2024
Sun Pharma and Taro announce merger agreement
Upon completion of the merger, Taro will become a privately held company and its shares will no longer be listed on the NYSE, the companies said18-01-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation under Regulation 30 about acquisition18-01-2024